Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines

AIDS

Volumn 28, Issue 17, 2014, Pages 2495-2504

  Clutton, Genevieve ^a   Carpov, Alexei ^b   Parks, Christopher L ^b   Dean, Hansi J ^b   Montefiori, David C ^c   Hanke, Tomáš ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibodies; BG505; Conserved regions; Heterologous prime boost regimen; HIV type 1 vaccine; HIVconsv; Modified vaccinia virus Ankara MVA; Simian adenovirus; T cells

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; PROTEOME; SUBUNIT VACCINE; VIRUS ANTIBODY; DRUG CARRIER; VIRUS ENVELOPE PROTEIN;

ADENOVIRIDAE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLADISTICS; CYTOKINE PRODUCTION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; INTRACELLULAR SPACE; MOUSE; NONHUMAN; POXVIRIDAE; PRIORITY JOURNAL; SIMIAN VIRUS; SPLEEN CELL; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; TREATMENT OUTCOME;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; B-LYMPHOCYTES; DRUG CARRIERS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV-1; MICE, INBRED BALB C; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINATION; VACCINES, SUBUNIT; VACCINIA VIRUS;

EID: 84927797395     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000468     Document Type: Article

References (45)

1. Hanke T. Conserved immunogens in prime-bost strategies for the next-generation HIV-1 vaccines. Expert Opin Biol Ther 2014; 14: 601-616.
2. Mc Michael AJ. Haynes BF. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol 2012; 13: 423-427.
3. Fischer W. Perkins S. Theiler J. Bhattacharya T. Yusim K. Funkhouser R. et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007; 13: 100-106.
4. Mothe B. Llano A. Ibarrondo J. Daniels M. Miranda C. Zamarreno J. et al. Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 2011; 9: 208.
5. Letourneau S. Im E-J. Mashishi T. Brereton C. Bridgeman A. Yang H. et al. Design and preclinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007; 2: e984.
6. Knudsen ML. Mbewe-Mvula A. Rosario M. Johansson DX. Kakoulidou M. Bridgeman A. et al. Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to conventional plasmid DNA vaccine. J Virol 2012; 86: 4082-4090.
7. Ondondo B. Brennan C. Nicosia A. Crome S. Hanke T. Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA ChAdV63 HIVconsv and MVA HIVconsv vaccines to BALB/c mice. Vaccine 2013; 31: 5594-5601.
8. Rosario M. Borthwick N. Stewart-Jones GB. Mbewe-Mwula A. Bridgeman A. Colloca S. et al. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 2012; 26: 275-284.
9. Rosario M. Bridgeman A. Quakkelaar ED. Quigley MF. Hill BJ. Knudsen ML. et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 2010; 40: 1973-1984.
10. Borthwick N. Ahmed T. Ondondo B. Hayes P. Rose A. Ebrahimsa U. et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 2014; 22: 464-475.
11. Simek MD. Rida W. Priddy FH. Pung P. Carrow E. Laufer DS. et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009; 83: 7337-7348.
12. Walker LM. Phogat SK. Chan-Hui PY. Wagner D. Phung P. Goss JL. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326: 285-289.
13. Hoffenberg S. Powell R. Carpov A. Wagner D. Wilson A. Kosakovsky Pond S. et al. Identification of an HIV-1 clade a envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. J Virol 2013; 87: 5372-5383.
14. Ringe RP. Sanders RW. Yasmeen A. Kim HJ. Lee JH. Cupo A. et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A 2013; 110: 18256-18261.
15. Kiepiela P. Ngumbela K. Thobakgale C. Ramduth D. Honeyborne I. Moodley E. et al. CD8R T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13: 46-53.
16. Masemola A. Mashishi T. Khoury G. Mohube P. Mokgotho P. Vardas E. et al. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8R T cells: correlation with viral load. J Virol 2004; 78: 3233-3243.
17. Rolland M. Heckerman D. Deng W. Rousseau CM. Coovadia H. Bishop K. et al. Broad and gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS ONE 2008; 3: e1424.
18. Zuniga R. Lucchetti A. Galvan P. Sanchez S. Sanchez C. Hernandez A. et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006; 80: 3122-3125.
19. Gaschen B. Taylor J. Yusim K. Foley B. Gao F. Lang D. et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296: 2354-2360.
20. Korber B. Gaschen B. Yusim K. Thakallapally R. Kesmir C. Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58: 19-42.
21. Goonetilleke N. Liu MK. Salazar-Gonzalez JF. Ferrari G. Giorgi E. Ganusov VV. et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206: 1253-1272.
22. McMichael AJ. Koff WC. Vaccines that stimulate T cell immunity to HIV-1: the next step. Nat Immunol 2014; 15: 319-322.
23. Warming S. Costantino N. Court DL. Jenkins NA. Copeland NG. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 2005; 33: e36.
24. Wang Z. Martinez J. Zhou W. La Rosa C. Srivastava T. Dasgupta A. et al. Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine 2010; 28: 1547-1557.
25. Hopkins R. Bridgeman A. Bourne C. Mbewe-Mwula A. Sadoff JC. Both GW. et al. Optimizing HIV-1-specific CD8R T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol 2011; 41: 3542-3552.
26. Gilljam G. Envelope glycoproteins of HIV-1. HIV-2. and SIV purified with Galanthus nivalis agglutinin induce strong immune responses. AIDS Res Hum Retroviruses 1993; 9: 431-438.
27. Mullarkey CE. Boyd A. van Laarhoven A. Lefevre EA. Veronica Carr B. Baratelli M. et al. Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NPRM1 coadministration with inactivated influenza vaccine. Eur J Immunol 2013; 43: 1940-1952.
28. Roshorm Y. Hong JP. Kobayashi N. McMichael AJ. Volsky DJ. Potash MJ. et al. Novel HIV-1 clade B candidate vaccines designed for HLA-BM5101R patients protected mice against chimaeric EcoHIV challenge. Eur J Immunol 2009; 39: 1831-1840.
29. Sarzotti-Kelsoe M. Bailer RT. Turk E. Lin CL. Bilska M. Greene KM. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods 2014; 409C: 131-146.
30. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19: 2673-2680.
31. Vesikari T. Pellegrini M. Karvonen A. Groth N. Borkowski A. O'Hagan DT. et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28: 563-571.
32. Ondondo B. Abdul-Jawad S. Bridgeman A. Hanke T. Characterization of T-cell responses to conserved regions of the HIV-1 proteome in the BALB/c mice. Clin Vaccine Immunol (in press).
33. Julien JP. Cupo A. Sok D. Stanfield RL. Lyumkis D. Deller MC. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013; 342: 1477-1483.
34. Kang YK. Andjelic S. Binley JM. Crooks ET. Franti M. Iyer SP. et al. Structural and immunogenicity studies of a cleaved. stabilized envelope trimer derived from subtype A HIV-1. Vaccine 2009; 27: 5120-5132.
35. Julien JP. Lee JH. Cupo A. Murin CD. Derking R. Hoffenberg S. et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A 2013; 110: 4351-4356.
36. Doria-Rose NA. Schramm CA. Gorman J. Moore PL. Bhiman JN. DeKosky BJ. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014; 509: 55-62.
37. Jardine J. Julien JP. Menis S. Ota T. Kalyuzhniy O. McGuire A. et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013; 340: 711-716.
38. Wibmer CK. Bhiman JN. Gray ES. Tumba N. Abdool Karim SS. Williamson C. et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 2013; 9: e1003738.
39. Haynes BF. Gilbert PB. McElrath MJ. Zolla-Pazner S. Tomaras GD. Alam SM. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366: 1275-1286.
40. Malherbe DC. Doria-Rose NA. Misher L. Beckett T. Puryear WB. Schuman JT. et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virol 2011; 85: 5262-5274.
41. Rerks-Ngarm S. Pitisuttithum P. Nitayaphan S. Kaewkungwal J. Chiu J. Paris R. et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-2220.
42. Rolland M. Edlefsen PT. Larsen BB. Tovanabutra S. Sanders-Buell E. Hertz T. et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012; 490: 417-420.
43. Gottardo R. Bailer RT. Korber BT. Gnanakaran S. Phillips J. Shen X. et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 2013; 8: e75665.
44. Yates NL. Liao HX. Fong Y. deCamp A. Vandergrift NA. Williams WT. et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 2014; 6: 228 ra239.
45. Zolla-Pazner S. deCamp A. Gilbert PB. Williams C. Yates NL. Williams WT. et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 2014; 9: e87572.